Galmed Pharmaceuticals (GLMD) EBITDA (2013 - 2024)
Galmed Pharmaceuticals (GLMD) posted quarterly EBITDA of $653000.0 for Q2 2024, up 13.96% year-over-year from $573000.0 in Q3 2023, and up 13.96% quarter-over-quarter from $573000.0 in Q2 2023.
Galmed Pharmaceuticals (GLMD) EBITDA (2013 - 2024) Analysis & Trends
Galmed Pharmaceuticals' EBITDA history runs 12 years deep, the most recent figure standing at $653000.0 for Q2 2024.
- In Q2 2024, EBITDA rose 13.96% year-over-year to $653000.0; the TTM figure through Jun 2024 stood at $1.5 million (up 30.22% YoY), while the FY2025 annual figure was $1.8 million, down 17.22% from the prior year.
- EBITDA for Q2 2024 stood at $653000.0, up from $573000.0 in the prior quarter.
- The five-year high for EBITDA was $408.6 million in Q3 2020, with the low at -$408.1 million in Q4 2020.
- The 5-year median for EBITDA is $309500.0 (2021), against an average of $330100.0.
- Peak annual rise in EBITDA reached 86112.87% in 2020, while the deepest fall reached 586.56% in 2020.
- Galmed Pharmaceuticals' EBITDA stood at -$408.1 million in 2020, then soared by 100.08% to $310000.0 in 2021, then sank by 110.97% to -$34000.0 in 2022, then jumped by 1785.29% to $573000.0 in 2023, then grew by 13.96% to $653000.0 in 2024.
- Business Quant data shows GLMD's EBITDA at $653000.0 in Q2 2024, $573000.0 in Q2 2023, and -$34000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 653,000.00 |
| Jun 30, 2023 | 573,000.00 |
| Sep 30, 2022 | -34,000.00 |
| Jun 30, 2022 | 286,000.00 |
| Sep 30, 2021 | 310,000.00 |
| Mar 31, 2021 | 309,000.00 |
| Dec 31, 2020 | -408.09 Mn |
| Sep 30, 2020 | 408.65 Mn |
| Jun 30, 2020 | -5.82 Mn |
| Mar 31, 2020 | 6.46 Mn |
| Dec 31, 2019 | 83.87 Mn |
| Sep 30, 2019 | 474,000.00 |
| Jun 30, 2019 | -4.70 Mn |
| Mar 31, 2019 | 4.04 Mn |
| Dec 31, 2018 | 4.06 Mn |
| Sep 30, 2018 | 1.23 Mn |
| Jun 30, 2018 | 118,000.00 |
| Mar 31, 2018 | 2.56 Mn |
| Dec 31, 2017 | 3.68 Mn |
| Sep 30, 2017 | 2.83 Mn |